published meta-analysis   sensitivity analysis   studies

anti-interleukin-6 in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsCORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51] CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80] Declercq J (COV-AID), 2021 1.02 [0.39; 2.66] EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06] EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72] NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31] NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88] NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18] Rutgers, 2021 0.59 [0.33; 1.06] Talaschian, 2021 1.56 [0.34; 7.13] Veiga, 2021 2.70 [0.92; 7.92] 0.75[0.52; 1.08]CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-ICU (Group 2), 2020, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04577534 (COVIDSTORM), 0, Rutgers, 2021, Talaschian, 2021, Veiga, 20211117%1,405moderatelow deathsdetailed resultsCORIMUNO-SARI-1 (non ICU), 2021 0.59 [0.23; 1.51] CORIMUNO-TOCI-1 (Group 1), 2020 0.92 [0.31; 2.71] CORIMUNO-TOCI-ICU (Group 2), 2020 0.64 [0.23; 1.80] Declercq J (COV-AID), 2021 1.02 [0.39; 2.66] EU-CTR2020-001375-32 (PreToVid), 0 0.59 [0.33; 1.06] EU-CTR2020-001748-24 (ImmCoVA), 0 1.25 [0.16; 9.72] NCT04434717 (COVITOZ-1 single dose plus two doses), 0 0.52 [0.01; 28.31] NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0 0.07 [0.01; 0.88] NCT04577534 (COVIDSTORM), 0 0.49 [0.01; 26.18] RCT-TCZ-COVID-19, 2021 2.24 [0.20; 25.37] RECOVERY, 2021 0.85 [0.76; 0.95] REMAP-CAP (tocilizumab), 2021 0.70 [0.51; 0.95] Rutgers, 2021 0.62 [0.36; 1.07] Soin AS (COVINTOC), 2021 0.67 [0.29; 1.55] Talaschian, 2021 1.25 [0.30; 5.14] Veiga, 2021 2.70 [0.92; 7.92] 0.82[0.75; 0.90]CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, CORIMUNO-TOCI-ICU (Group 2), 2020, Declercq J (COV-AID), 2021, EU-CTR2020-001375-32 (PreToVid), 0, EU-CTR2020-001748-24 (ImmCoVA), 0, NCT04434717 (COVITOZ-1 single dose plus two doses), 0, NCT04479358 (COVIDOSE-2 substudy A 120mg plus 40mg), 0, NCT04577534 (COVIDSTORM), 0, RCT-TCZ-COVID-19, 2021, RECOVERY, 2021, REMAP-CAP (tocilizumab), 2021, Rutgers, 2021, Soin AS (COVINTOC), 2021, Talaschian, 2021, Veiga, 2021160%6,707moderatelow deaths (time to event analysis only)detailed resultsRutgers, 2021 0.62 [0.36; 1.07] Talaschian, 2021 1.25 [0.30; 5.14] 0.68[0.41; 1.13]Rutgers, 2021, Talaschian, 202120%394moderatenot evaluable clinical deteriorationdetailed resultsCORIMUNO-SARI-1 (non ICU), 2021 1.01 [0.48; 2.12] CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.26; 1.20] RCT-TCZ-COVID-19, 2021 1.05 [0.59; 1.86] Soin AS (COVINTOC), 2021 0.67 [0.26; 1.77] 0.85[0.59; 1.22]CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, RCT-TCZ-COVID-19, 2021, Soin AS (COVINTOC), 202140%576moderatenot evaluable clinical improvementdetailed resultsDongsheng Wang, 2020 2.37 [0.40; 13.96] REMAP-CAP (tocilizumab), 2021 1.64 [1.25; 2.15] 1.65[1.27; 2.16]Dongsheng Wang, 2020, REMAP-CAP (tocilizumab), 202120%820moderatenot evaluable death or ventilationdetailed resultsCORIMUNO-SARI-1 (non ICU), 2021 1.12 [0.56; 2.22] CORIMUNO-TOCI-1 (Group 1), 2020 0.56 [0.24; 1.31] RECOVERY, 2021 0.85 [0.78; 0.93] Rutgers, 2021 0.65 [0.43; 0.99] Veiga, 2021 1.54 [0.65; 3.63] 0.84[0.69; 1.01]CORIMUNO-SARI-1 (non ICU), 2021, CORIMUNO-TOCI-1 (Group 1), 2020, RECOVERY, 2021, Rutgers, 2021, Veiga, 2021518%4,312moderatenot evaluable mechanical ventilationdetailed resultsRCT-TCZ-COVID-19, 2021 1.36 [0.39; 4.69] Rutgers, 2021 0.65 [0.35; 1.24] Soin AS (COVINTOC), 2021 1.05 [0.46; 2.38] 0.84[0.53; 1.35]RCT-TCZ-COVID-19, 2021, Rutgers, 2021, Soin AS (COVINTOC), 202130%659moderatenot evaluable ICU admissiondetailed resultsRutgers, 2021 0.96 [0.55; 1.68] Soin AS (COVINTOC), 2021 1.33 [0.67; 2.64] 1.09[0.71; 1.68]Rutgers, 2021, Soin AS (COVINTOC), 202120%533moderatenot evaluable recoverydetailed resultsTalaschian, 2021 0.64 [0.14; 2.92] 0.64[0.14; 2.92]Talaschian, 202110%36NAnot evaluable serious adverse eventsdetailed resultsDongsheng Wang, 2020 0.91 [0.02; 47.31] Soin AS (COVINTOC), 2021 0.97 [0.44; 2.13] Talaschian, 2021 7.93 [0.37; 171.38] Veiga, 2021 1.66 [0.60; 4.59] 1.27[0.70; 2.32]Dongsheng Wang, 2020, Soin AS (COVINTOC), 2021, Talaschian, 2021, Veiga, 202140%410moderatenot evaluable adverse eventsdetailed resultsDongsheng Wang, 2020 9.64 [2.76; 33.75] Soin AS (COVINTOC), 2021 1.50 [0.78; 2.87] Veiga, 2021 1.65 [0.81; 3.37] 2.47[1.00; 6.10]Dongsheng Wang, 2020, Soin AS (COVINTOC), 2021, Veiga, 2021372%374moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-03-28 23:11 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 557,635,1236,553,628,646,645,607,395 - roots T: 290